NCT01027377View on ClinicalTrials.gov

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

May 31, 2011

Conditions
Severe Hemophilia A
Interventions
DRUG

rFVIIIFc

Single dose

DRUG

rFVIIIFc

Single dose

Trial Locations (7)

Unknown

Research Site, Los Angeles

Research Site, Sacramento

Research Site, Waltham

Research Site, Pittsburgh

Research Site, Seattle

Research Site, Hong Kong

Research Site, Tel Aviv

Sponsors
All Listed Sponsors
lead

Bioverativ Therapeutics Inc.

INDUSTRY

NCT01027377 - Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A | Biotech Hunter | Biotech Hunter